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a  b  s  t  r  a  c  t
It is  well  established  that  the  infectious  agent  of scrapie  can  replicate  in the  lymphoreticular
system  (LRS).  However,  the  effects  of  removal  of  LRS  target  tissues  on  the  pathogenesis  of
the  infection  and  the  accumulation  of disease-associated  prion  protein  (PrPd) in LRS  tissues
on specific  immune  cell subsets  are  poorly  understood  aspects.  To  address  these  questions
16 ARQ/ARQ  sheep  were  subcutaneously  inoculated  in  the  drainage  area  of the  prefemoral
lymph  node  with  brain  homogenate  derived  from  Suffolk  sheep  naturally  infected  with
scrapie.  Fourteen  sheep  were  then  subjected  to  either  early  (14–17  days  post-inoculation
[dpi])  or  late (175–201  dpi)  lymphadenectomy  and  culled  at  preclinical  or  clinical  stages
of infection.  Neither  late  nor  even  early lymphadenectomy  prevented  infection  or  had  any
effect on  the  accumulation  of PrPd in the  LRS  or CNS  suggesting  a rapid  organic  dissemina-
tion  of  the  infectious  agent  after  inoculation.  Lymph  nodes  from  eight  scrapie  inoculated
sheep  selected  on  the basis  of  the  amount  of  PrPd in  their LRS  tissues  (negative,  low  or
high)  were  examined  for  six  different  immune  cell markers.  The  PrPd negative  lymph  nodes
from two  sheep  with  no  evidence  of  scrapie  infection  showed  lower  numbers  of  cluster  of
determination  (CD)  21  positive  cells  than  PrPd positive  nodes,  irrespective  of  their location
(hind leg  or  head).  However,  quantitative  differences  in  the  expression  of  this  marker  were
not  detected  when  comparing  lymph  nodes  with  low and  high  levels  of  PrPd accumula-
tion,  suggesting  that  proliferation  of  CD21  positive  cells  is  related  to  scrapie  infection,  but
not directly  linked  to  the magnitude  of  PrPd accumulation.  An  additional  observation  of  the
study was  that  sheep  that  were  methionin–threonine  at  codon  112  of the  prion  protein  gene
showed  lower  attack  rates  than methionine  homozygotes  (67%  and  100%,  respectively)  and
also  generally  lower  levels  of  PrPd accumulation  in  the  LRS  and  brain  and  increased  survival
times, suggesting  an  influence  of  such  polymorphism  in  the  susceptibility  to scrapie.
© 2013 Elsevier B.V. All rights reserved.
∗ Corresponding author. Tel.: +44 0131 445 5111;
fax: +44 0131 445 6235.
E-mail address: francesca.chianini@moredun.ac.uk (F. Chianini).
1. Introduction
Transmissible spongiform encephalopathies (TSEs) are
a group of infectious neurodegenerative diseases affecting
animals and humans (Hur et al., 2002). Long incubation
periods are a well documented characteristic of TSEs but
tissues can become infectious long before the onset of
0165-2427/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
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clinical signs (Carp et al., 1994; Hadlow et al., 1982). Recent
studies have provided strong evidence to support the pro-
tein only hypothesis (Prusiner, 1982) which proposes a
misfolded version (PrPSc) of the normal cellular prion pro-
tein (PrPc) as the infectious agent (Chianini et al., 2012; Kim
et al., 2010; Legname et al., 2004; Makarava et al., 2010;
Wang et al., 2010). This pathological form of the prion pro-
tein is also called protease-resistant prion protein (PrPres)
and is primarily used when referring to western blot (WB)
results, or disease-associated prion protein (PrPd) when
referring to immunohistochemistry (IHC).
Scrapie is a TSE that affects sheep and goats and has been
reported in Great Britain since the mid  eighteenth century
(Parry, 1983). The prion protein gene (Prnp), which encodes
for the cellular protein PrPc, is an important determinant of
the susceptibility of sheep to scrapie (Hunter et al., 1997),
although there are uncertainties as to why and how poly-
morphisms of that gene are influential with respect to
susceptibility (Baylis and Goldmann, 2004). Sheep of the
Suffolk and Romney breeds which are ARQ/ARQ (amino
acids at codons 136, 154 and 171, respectively) are gener-
ally susceptible to natural and experimental scrapie, but it
has been shown that sheep with one Prnp allele encoding
for threonine (T) at codon 112 have reduced susceptibil-
ity compared to sheep homozygous for methionine (M;
Ikeda et al., 1995; Laegreid et al., 2008; González et al.,
2012).
In sheep, oral exposure to the scrapie agent results in
accumulation of disease-associated PrP (PrPd) initially in
the lymphoid tissues of the alimentary tract such as the
retropharyngeal lymph node and the ileal Peyer’s patches
(Hadlow et al., 1982; van Keulen et al., 2002). However it is
not known whether this initial accumulation is restricted to
such tissues or is simultaneous with an early organic dis-
semination, as other studies suggest (Jeffrey et al., 2006;
Dagleish et al., 2010). It is also well known that the subcu-
taneous route is efficient for transmission of experimental
scrapie to mice (Kimberlin and Walker, 1979; Lasmezas
et al., 1996) and sheep (Houston et al., 2002). This route
provides an opportunity to answer the question of local
restriction versus early dissemination of the infectious
agent by removal of the drainage lymph node of the area of
subcutaneous challenge, even though the pathways (lymph
or blood) or cells (if any) involved in the dissemination of
the infectious agent from the point of subcutaneous inoc-
ulation to lymphoreticular system (LRS) tissues and other
organs are not fully understood, particularly in the natural
sheep host.
Additionally, little is known about the relevance of the
LRS involvement in the pathogenesis of scrapie, and also
it is generally believed there is no specific immunological
response to infection. However, it has been shown by ultra-
structural studies of scrapie infected mice that changes
in development and maturation occur in secondary fol-
licles of the spleen and lymph nodes (McGovern et al.,
2004). There is also evidence suggesting that several cell
types, such as follicular dendritic cells (FDCs), tingible body
macrophages (TBM) and B cells, are involved in different
aspects of the pathogenesis of scrapie in the LRS (Brown
et al., 2009; Eaton et al., 2007, 2009; McGovern et al., 2009;
Mabbott, 2012). Moreover, it has been shown that PrPc is
present in immature immunocytes and T cells (Kubosaki
et al., 2003), although studies on the role of those cells in
the pathogenesis of the disease are limited. More recently,
plasmacytoid dendritic cells were found to play a key role
in sequestering prion titres at an early stage of infec-
tion in mice (Castro-Seoane et al., 2012). However, most
of those studies have been carried out either on trans-
genic mice or using flow cytometry, and in both cases
the availability of primary antibodies is greater than for
IHC in ovine fixed tissues. However, if ovine tissues are
fixed using a zinc-salt solution rather than formalin, the
possibility to label FDCs, B and T cells is increased either
using antibodies specifically raised against ovine epitopes
or antibodies that cross reacts with them (González et al.,
2001).
The experiment reported here aimed primarily to deter-
mine if surgical removal of the lymph node local to the
injection point had an effect on the progression of scrapie
in sheep and to assess whether the changes in immune sys-
tem cell subsets were qualitatively and/or quantitatively
associated with PrPd accumulation in LRS tissues. The paper
also describes the kinetics of PrPd accumulation in LRS and
central nervous system (CNS) tissues in relation with poly-
morphisms at codon 112 of PrP.
2. Materials and methods
2.1. Animals and experimental design
Individual details of the sheep used are provided in
Table 1 and illustrated in Fig. 1. Seventeen ARQ/ARQ lambs
of Suffolk or Romney breed (where letters indicate amino
acid codes at codon 136 [A, alanine], 154 [R, arginine] and
171 [Q, glutamine] of the prion protein) were obtained from
a New Zealand-derived, scrapie-free flock (Arthur Rick-
wood Sheep Unit, AHVLA, Weybridge, UK). At 6 months of
age, 16 lambs were injected subcutaneously in the drainage
area of the right prefemoral lymph node with 1 ml  of a
10% clarified scrapie positive brain pool homogenate (SBH)
derived from Suffolk sheep, as described previously (Eaton
et al., 2007). One lamb was  inoculated with a similarly pre-
pared scrapie negative brain homogenate from a Suffolk
sheep for negative control purposes.
To determine the effect of lymphadenectomy, seven
lambs inoculated with SBH were subjected to surgical
removal of the ipsi- (site of injection) and contra-lateral
prefemoral lymph nodes at 13–16 days post inocula-
tion (dpi; early lymphadenectomy [EL]), another seven at
169–201 dpi (late lymphadenectomy [LL]), and two sheep
were not subjected to this surgical procedure (positive
controls). Animals were monitored for clinical signs of
scrapie following a previously reported end-point scoring
system (González et al., 2012). All seven sheep of the EL
group and four of the LL group were culled at a preclinical
stage, between 478 and 529 dpi (together with the nega-
tive control sheep), and three animals from the LL group
and the two  positive control animals were killed when
they reached clinical end point (Table 1 and Fig. 1). All
animal procedures complied with the Animals (Scientific
Procedures) Act 1986 and were approved by the Moredun
Research Institute ethics committee.
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Table 1
Details of the ARQ/ARQ sheep used in the study.
ID. Codon 112
genotype
Lymphadnectomy Clinical status PM dpi PrPd presence or score CD marker study
Group dpi ENS Trig Nod CMG CNS LRS
J165 MT EL 16 pre 478 N N N N 2 3.6 Low PrP
J093 MT EL  16 pre 490 N N N N 0 13.6 Low PrP
J156* MT  EL 13 pre 529 N N N P 9 46.4 High PrP
J160  MM EL 17 (ipsi +) pre 491 N P N P 15 43.2 High PrP
J162* MM EL 14 pre 511 P P N P 14 36.2
8803* MM EL 16 pre 513 P N N N 10 25.5
J187 MM EL 16 pre 486 P P N P 10 23.9
J169 MT  LL 175 pre 478 N N N N 0 0 No PrP
J137 MT  LL 194 pre 504 N N N N 0 0 No PrP
J184 MM LL 185 pre 483 P N N N 3 38.7
603  MM LL 199 pre 513 P N N N 10 43.4
J149 MM LL 169 clin 743 P P P P 30 52.1
J117 MM LL 201 (ipsi +) clin 763 P P na P 30 50.3 Clinical
J103  MM LL 184 (contra +) clin 810 P P N N 29 41.4 Clinical
J147  MT  + Control ND clin 1188 P P P P 30 48.4
J153  MM + Control ND clin 578 P P N P 26 41.8
J182 MT − Control 16 neg 493 N N N N 0 0
ID, sheep identification number (in bold those selected for the CD markers study and in the last column their category); Lymphadenectomy: EL, early; LL,
late;  dpi, days post-infection: the lymph nodes that showed positive PrPd immunolabelling are indicated as (ipsi +) or (contra +); the rest of the excised
lymph nodes were negative. ND, not done. Clinical status at post-mortem (PM): pre, preclinical; clin, clinical; neg, negative. ENS, enteric nervous system;
Trig,  trigeminal nerve; Nod, nodose ganglion; CMG, cranial mesenteric ganglion; CNS, central nervous system; LRS, lymphoreticular system (the scores do
not  take into account the prefemoral lymph nodes subjected to lymphadenectomy); N, negative; P, positive; ns, not sampled.
* Lymph was  consistently obtained from these animals for 3–4 days after challenge.
2.2. Tissue sampling at post-mortem and IHC procedures
Sheep were killed by intra-venous barbiturate overdose.
At post-mortem examination the following tissues were
collected, fixed in 10% buffered formalin and processed for
IHC detection of PrPd: central nervous system (CNS): half
brain sagittally sliced, and samples of the cervical, thoracic
and lumbar segments of the spinal cord. Peripheral nervous
system (PNS): trigeminal, nodose and cranial mesenteric
ganglia, and enteric nervous system (ENS) of the jejunum,
distal ileum and colon. LRS tissues: Peyer’s patches in the
jejunum and distal ileum, lymphoid follicles in the colon,
plus proximal and distal jejunal, medial retropharyngeal,
submandibular, popliteal, inguinal and prescapular lymph
nodes (LNs), palatine tonsil and spleen. With paired tissues,
samples were taken from both sides.
Four m-thick sections of each of the formalin-fixed
tissues above were mounted on glass microscope slides
and subjected to antigen retrieval procedures (immer-
sion in formic acid followed by citrate buffer autoclaving)
and immunolabelling for PrPd as described previously
(González et al., 2002). Tissues were incubated overnight
at 24 ◦C with a primary monoclonal antibody, R145, which
recognises the 222–226 amino acid sequence of ovine PrP
(Jeffrey et al., 2006). The IHC procedure was completed
by an immunoperoxidase method using diaminobenzidine
(DAB) as chromagen and Mayer’s haematoxylin for coun-
terstaining.
For identification of immune cell subsets, samples
of medial retropharyngeal, submandibular, inguinal and
popliteal LNs adjacent to those fixed in 10% buffered forma-
lin, and both ipsi- and contra-lateral to the side of injection,
were immersed in zinc salts fixative, processed routinely
and embedded in paraffin-wax as described previously
(González et al., 2001). Five m-thick serial sections of
those samples were mounted on glass microscope slides
and subjected to IHC using a panel of monoclonal antibod-
ies against T cell, B cell and FDC cluster of determination
(CD) markers, as detailed in Table 2. After quenching
endogenous tissue peroxidase activity and blocking non-
specific binding, sections were incubated overnight at 4 ◦C
with the different primary antibodies and visualised using
the EnVisionTM System-HRP (Dako, Ely, UK), using DAB as
the chromagen and Z haematoxylin for counterstaining as
Grou p 1
Grou p 2
+ve controls
-ve  control
T MTM MM T
T M T M M M M
M T
d0 d13-16 d1 69-201 d4 78-529 d7 43-810d578 d1118
T
Fig. 1. Schematic representation of the experimental design and outcome overview. Circles represent day of subcutaneous injection (d0) of sheep with
scrapie  brain pool (red) or normal brain (green). Diamonds represent day post-infection at which lymphadenectomies were performed. Letters represent
days  post-infection (black, preclinical stage; red, clinical stage) at which post-mortem were carried out in individual sheep: M = methionine homozygotes
at  codon 112; T = methionine–threonine heterozygotes at codon 112; red letter = scrapie confirmed by IHC; black letter = no evidence of scrapie on IHC
examination investigation of full set of tissue samples as described in the text.
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Table  2
CD markers, cell types recognised and antibody details.
CD marker Cell type Ab clone Dilution Source Reference
CD3 T lymphocytes F7.2.38 1/200 Dako (Alibaud et al., 2000)
CD4  T-helper cells 17D 1/400 Basel (Mackay et al., 1988)
CD8  T-cytotoxic cells 7C2 1/400 MRI  (Naessens et al., 1997)
TCR   T cells 86D 1/400 Basel (Mackay and Hein, 1989)
CD21 FDCs, Mature B cells CC21 1/400,000 IAH (Naessens et al., 1997)
CD79cy B cell lineage HM57 1/100 Dako (Mason et al., 1991)
CD, cluster of determination. TCR, T cell receptor. Ab, antibody (all murine IgG1 monoclonal antibodies). Sources are: Dako, Dako UK Ltd., Ely, UK; Basel,
Basel  Institute for Immunology, Basel, Switzerland; MRI, Moredun Research Institute; IAH, Institute for Animal Health, Compton Laboratory, Newbury, UK.
described previously (González et al., 2001). These exami-
nations were conducted on 8 of the 16 scrapie-inoculated
sheep, which were selected on the basis of their PrPd scores
in CNS and LRS tissues which were obtained following the
methods described below.
2.3. Scoring and quantification of PrPd and immune cell
subsets
Accumulation of PrPd in the CNS was scored subjectively
from 0 (absence) to 3 (abundant) in intervals of 0.5 in each
of the following brain areas: frontal cerebral cortex, corpus
striatum, thalamus/hypothalamus, midbrain, cerebellum,
rostral medulla oblongata, obex and spinal cord at cervical,
thoracic and lumbar segments following criteria previously
described and illustrated (González et al., 2005; Sisó et al.,
2010a,b). For each animal, the total magnitude of PrPd in
the CNS was expressed as the sum of the scores in the dif-
ferent areas, so that the range for each individual sheep
was from 0 to 30. Accumulation of PrPd in PNS tissues was
scored as positive or negative. The degree of involvement
of the different LRS tissues was determined by a combina-
tion of the percentage of positive lymphoid follicles and the
magnitude of PrPd labelling within them (from 1 = labelling
confined to a few TBMs in the light zone, to 5 = intense
labelling of TBMs in light and dark zones and also of FDCs),
as previously detailed (Martin et al., 2005). This method
was not applied to spleen samples, which were subjectively
scored from 0 to 3.
The results of the quantification of PrPd deposition in
LRS and CNS tissues were used to select eight sheep: two
devoid of PrPd labelling, two each with low and high PrPd
scores at the preclinical stage of disease, and two  with high
PrPd scores at clinical end point (Table 1). For each cho-
sen sheep, the cortices of the eight lymph nodes specified
above were examined for immunoreactivity to the differ-
ent CD markers. This was subjectively scored from 0 to
5 in each of 50 microscopic fields (25 in secondary fol-
licles and 25 in paracortex, both at 400× magnification),
where 0 = no positive cells, 1 = few scattered positive cells,
2 = increasing number of positive cells still with a scattered
distribution; 3 = moderate number of positive cells occu-
pying 1/3 of the region, 4 = high number of positive cells
diffusely distributed, and 5 = highest number of positive
cells with a widespread distribution and clear predomi-
nance over non-labelling cells. The mean value for each
of the cell markers, generated from the single values given
for the different microscopic fields examined, was assigned
to each area (follicles and paracortex), and the two  values
were added to give a total score (from 0 to 10) for each
lymph node, which was  used for statistical analysis.
2.4. PrP genotyping
Prior to undertaking the experiment, only amino acids
at codons 136, 154 and 171 of the ovine PrP gene were
determined by sequencing with an ABI Prism 377 DNA
sequencer according to the manufacturer’s instructions
(PE Applied Biosystems; Warrington, UK). At the end of
the experiment, in view of information regarding the
influence of polymorphisms at codon 112 on the sus-
ceptibility of Suffolk sheep to scrapie (Ikeda et al., 1995;
Laegreid et al., 2008), brain tissue samples from all 17
sheep were sequenced. Chromosomal DNA was  extracted
from brain tissue using DNeasy blood and tissue kit
(QIAGEN) and then used as a template for PCR using Hot-
StarTaq DNA polymerase (QIAGEN) with forward primer
313 (5′-GTCAAGGTGGTAGCCACAGTCAGTG-3′) and reverse
primer 316 (5′-GCTCCACCACTCGCTCCATTATCTTG-3′). PCR
was performed in a Hybaid MBS  0.2G Thermal Cycler, and
included 5 min  of initial denaturation at 95 ◦C, followed by
30 cycles of 94 ◦C for 30 s, 55 ◦C for 30 s and 72 ◦C for 1 min.
The amplified product from each reaction was  purified
(QIAGEN kit) and sequenced in both directions by Eurofins
MWG  Operon using the same primers. All sequences were
compared at the nucleotide level and translated to provide
the corresponding amino acid sequence. DNA and amino
acid sequences were compared using SeqMan software
(DNASTAR, Inc.) to determine the presence of M or T at
codon 112.
2.5. Statistical analyses
Where sufficient number of data were available,
unpaired t-tests (parametric when data were normally
distributed or non-parametric [Mann–Whitney] for data
not-normally distributed) were used to determine the
effect of polymorphisms at codon 112 on the magnitude
of PrPd accumulation in the CNS and LRS for sheep at pre-
clinical and clinical stages of infection. Paired t-tests were
employed to evaluate differences in magnitudes of PrPd
accumulation between paired LRS tissues (palatine tonsil
and LNs with the exception of those draining the gut) ipsi-
and contra-lateral to the site of injection. Unpaired t-tests
were also used to determine the existence of differences
between preclinical and clinical cases in terms of magni-
tude of PrPd deposition in LRS and CNS compartments, and
Author's personal copy
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paired t-tests for the pair-wise comparison of PrPd accu-
mulation in the different LRS tissues examined.
To determine any positive or negative association
between the magnitude of PrPd deposition and the quan-
titative expression of the different immune cell markers
explored, unpaired t-tests (parametric or non-parametric,
as specified above) were used to compare the four different
sheep groups established according to their PrPd load and
clinical status.
3. Results
3.1. General pathogenetical aspects: distribution of PrPd
and effect of polymorphisms at codon 112
Fourteen of the 16 sheep inoculated subcutaneously
with SBH became infected as demonstrated by the IHC
detection of PrPd in one or more of the tissues examined,
giving an overall attack rate of 88.2%. The negative control
sheep inoculated with Suffolk sheep derived scrapie-
negative brain pool homogenate and killed at 493 dpi was
devoid of any PrPd immunolabelling (Table 1 and Fig. 1).
Only one of the five sheep left to develop clinical dis-
ease was M112T (M,  methionine; T, threonine) at codon
112 (Table 1 and Fig. 1); this sheep was a positive con-
trol, not subjected to lymphadenectomy, and was killed
when it reached clinical end point after a much more pro-
tracted incubation period (1118 dpi) than the other clinical
cases (724 ± 101 days [mean ± standard deviation]). How-
ever, the magnitude and distribution of PrPd in that sheep
was similar to the other clinical cases (Table 1). Of the
11 sheep culled at a preclinical stage, five were heterozy-
gote (M112T) and six were homozygote (M112M;  Table 1
and Fig. 1). Despite being killed at similar times after inoc-
ulation (average 496 and 500 dpi, respectively), two  of
the heterozygote sheep were completely negative for PrPd
and another two showed low levels of PrPd in LRS tissues
(one of these was negative in the CNS). Statistical analyses
showed significantly less accumulation of PrPd in heterozy-
gote sheep when compared to the homozygote sheep in
both LRS (13.2 ± 20.7 and 37.6 ± 7.9, respectively; P < 0.05)
and CNS (2.2 ± 3.9 and 11.3 ± 4.8, respectively; P < 0.01)
when data from the two  PrPd negative sheep are included.
If the analysis is restricted to the three PrPd positive het-
erozygote sheep, the difference in accumulation of PrPd
was not significant in the LRS (22 ± 23.7 and 37.6 ± 7.9
for heterozygote and homozygote sheep, respectively) but
remained significant for the CNS (3.7 ± 4.7 and 11.3 ± 4.8,
respectively; P < 0.05).
Accumulation of PrPd in the PNS samples examined was
variable among the nine scrapie positive sheep culled dur-
ing the preclinical phase (Table 1): two sheep were negative
in all nervous tissues examined (J165, J093), the trigeminal
ganglion was positive in three (J160, J162, J187), the cranial
mesenteric ganglion in four (J156, J160, J162, J187) and the
ENS in five (J162, 8803, J187, J184, 603), while the nodose
ganglion was negative in all of them. All sheep showing
PrPd in PNS tissues were positive not just in the LRS but
also in the CNS. Among the five clinical cases, four accumu-
lated PrPd in the cranial mesenteric ganglion (J149, J117,
J147, J153) and two  in the nodose ganglion (J149, J147),
while all were positive in the ENS and trigeminal ganglion
(Table 1).
Accumulation of PrPd in LRS tissues was confirmed in 9
of 11 preclinical and 5 of 5 clinical scrapie cases (Table 1),
but with differences in magnitude and extent, which
were associated with their sampling points post infection
(p.i.) (499 ± 17 dpi vs. 802 ± 197 dpi, for preclinical and
clinical cases, respectively; P = 0.001). Thus, while all 16
LRS tissues examined in clinically affected sheep showed
PrPd accumulation, three of the preclinical cases showed
incomplete involvement of the same LRS tissues. Clinically
affected sheep also showed significantly higher levels of
PrPd accumulation in LRS tissues (48.7 ± 6.1 [mean ± SD])
than preclinical cases (32.4 ± 15.6; P < 0.05). This quanti-
tative difference was  due to three of the preclinical cases
showing total values of 3.6, 13.6 (both M112T) and 23.9
(M112M);  if these sheep are excluded from the comparison
the differences in LRS PrPd load became non-significant,
despite incubation periods being still significantly different
(507 ± 17 vs. 802 ± 197 for six preclinical and five clinical
cases, respectively; P < 0.01). Fig. 2 represents the magni-
tude of PrPd accumulation in the LRS of scrapie infected
sheep at different stages of preclinical infection and clinical
disease.
Details of PrPd scores in individual LRS samples of
each sheep examined are given in Supplementary Table
1. With the exception of the popliteal LNs of one preclin-
ical sheep, in which the right (ipsi-lateral) LN was  negative
and the left node positive, PrPd accumulation of paired
LRS tissues was  always bilateral and with no significant
differences in magnitude neither among preclinical nor
among clinical cases (results of statistical analyses not
shown but can be inferred from data in Supplementary
Table 1). When comparing the different LRS tissues exam-
ined (with the exception of the spleen for which the scoring
system differed) from scrapie positive sheep, significantly
higher levels of PrPd accumulation were present in those
located in the head (palatine tonsil, retropharyngeal and
submandibular LNs; combined score 2.8 ± 1.2) compared
to the inguinal, pre-scapular and popliteal LNs (superfi-
cial LNs, with a combined score of 2.0 ± 1.2 [P < 0.001]).
The gut-associated LRS tissues (Peyer’s patches and distal
and proximal jejunal LNs) provided intermediate results
(2.5 ± 1.2), which were significantly higher (P < 0.05) than
the group of superficial LNs (inguinal, pre-scapular and
popliteal) but not significantly different to the LNs of the
head (palatine tonsil, retropharyngeal and submandibular).
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.vetimm.2013.01.005
The total magnitude of PrPd accumulation in the CNS
of scrapie challenged sheep ranged from 0 to 30 (Table 1),
and appear to vary depending on several factors. Preclin-
ical scrapie positive cases showed magnitudes significantly
lower than clinically affected sheep (8.8 ± 5.9 vs. 29.0 ± 1.7
respectively; P < 0.001), and such differences were main-
tained if the three cases with the lowest PrPd accumulation
in LRS mentioned above were excluded from the compar-
ison. In other words, preclinical (n = 6) and clinical (n = 5)
sheep with no significant differences in accumulation of
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Fig. 2. Schematic representation of the average magnitude of total PrPd in the lymphoid tissues (LTs, blue circles, against Y1 axis) and in the CNS (gold,
against Y2 axis) of preclinical (left of the dotted bar; n = 9) and clinical (right of the dotted bar; n = 5) scrapie cases, with reference to days post-inoculation
(dpi)  at which post-mortem examinations were performed.
PrPd in the LRS tissues showed significant differences in
magnitude of accumulation of PrPd in the CNS (11.2 ± 4.9
vs. 29.0 ± 1.7 respectively; P < 0.001) and these were asso-
ciated with different sampling points d.p.i. as stated above.
Within the preclinical scrapie cases, M112T sheep showed
PrPd accumulation in the CNS of magnitudes between 0 and
9, while for M112M sheep the magnitudes were between
3 and 16. These differences were statistically significant
(P < 0.05) using the Mann–Whitney test. Fig. 2 shows the
magnitude of PrPd accumulation in the CNS of scrapie
infected sheep at different stages of preclinical infection
and clinical disease.
Regarding the topographical distribution within the
CNS, in preclinical cases PrPd accumulated more often and
with highest magnitudes in the medulla oblongata, in the
hypothalamus and in the spinal cord examined, whereas in
forebrain areas it accumulated the least. PrPd accumulation
in clinical cases was widespread and severe in all areas of
the CNS examined.
3.2. Effect of lymphadenectomy on the magnitude and
distribution of PrPd
Among the five sheep which progressed to clinical
disease, the one that had not been subjected to lym-
phadenectomy reached clinical end point at a slightly
earlier time point (578 dpi) than the three which had their
prefemoral lymph nodes excised at a late time point after
challenge (743–810 dpi). As described above, the positive
control sheep (not subjected to lymphadenectomy) devel-
oped scrapie at a later stage (1118 dpi) but was  a M112T
heterozygote. All the five clinical cases showed similar
amounts of PrPd in the LRS and CNS samples examined
(Table 1), regardless of lymphadenectomy. Among the pre-
clinical cases, similar magnitudes of PrPd in LRS and CNS
were found in sheep killed at similar dpi after being sub-
jected to either EL or LL. The two sheep that were negative
for PrPd, both M112T, were LL cases while the three EL cases
that were also M112T were positive in LRS tissues (two of
them also in the CNS).
Examination of the excised prefemoral LNs to detect
PrPd revealed only one positive (ipsi-lateral) lymph node
of 14 collected from the EL group and two  positive lymph
nodes from two  different animals (one ipsi- and one contra-
lateral) of 14 collected from the LL group. All three PrPd
positive lymph nodes were from M112M sheep. Cannula-
tion of the afferent lymphatics of the prefemoral lymph
nodes, where lymph was  consistently obtained before and
3–4 days after subcutaneous injection of scrapie inoculum,
was successfully achieved in three out of seven animals.
The samples of lymph were not considered sufficient for
further studies, however its removal did not affect the
progression to disease and the three sheep (identified in
Table 1) showed abundant PrPd deposition in both LRS and
CNS samples when killed during the preclinical stage of
infection.
3.3. Changes in immune system cell subsets in relation to
PrPd accumulation
As significant differences in PrPd accumulation were
observed between the lymph nodes situated in the head
compared to those draining hind leg structures in the two
groups of highest PrPd accumulation (see above), the two
areas were analysed separately. However, because the two
preclinical sheep with high levels of PrPd accumulation and
the two clinically affected sheep showed almost identical
magnitudes PrPd in the eight lymph nodes examined, the
two groups were merged together as a “high PrPd” group
(Table 3).
The results of the quantitative analyses of the expres-
sion of the different CD markers between those three sheep
groups (negative, low and high PrPd) in the two areas
(head and leg), as explained above, are detailed in Table 3
and illustrated in Figs. 3 and 4. For T-lymphocyte markers
CD3, CD4 and CD8, no significant differences were found
between the three sheep groups in any of the two  areas.
For TCR positive cells the PrPd negative group showed
significantly lower scores in the LNs of the head (4.6 ± 0.6)
than the other two groups (P < 0.01), although the highest
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Table 3
Immune cell markers reactivity in lymph nodes accumulating different
levels of PrPd.
(a) Negative Low High Clinical
3.3 ± 0.2 3.4 ± 0.6
PrPd 0.0 0.9 ± 1.0 3.4 ± 0.4
CD3 8.3 ± 0.8 8.7 ± 0.4 8.5 ± 0.5
CD4 7.7 ± 0.4 8.2 ± 0.5 7.7 ± 0.5
CD8 6.6 ± 0.6 6.3 ± 0.5 6.2 ± 1.3
TCR 4.6 ± 0.6 6.5 ± 0.9 5.7 ± 0.8
CD79 8.2 ± 0.7 8.3 ± 0.5 7.8 ± 0.7
CD21 7.3 ± 0.6 7.9 ± 0.3 8.2 ± 0.5
(b) Negative Low High Clinical
3.1 ± 0.3 2.5 ± 0.8
PrPd 0.0 0.2 ± 0.3 2.8 ± 0.7
CD3 8.4 ± 0.8 9.0 ± 0.4 8.7 ± 0.5
CD4 8.3 ± 0.6 8.0 ± 0.4 8.0 ± 0.5
CD8 6.6 ± 0.8 6.1 ± 0.6 6.3 ± 1.0
TCR 6.6 ± 0.5 6.7 ± 0.4 6.3 ± 0.6
CD79 8.2 ± 0.6 8.3 ± 0.5 7.8 ± 0.7
CD21 7.7 ± 0.7 8.5 ± 0.5 8.3 ± 0.5
Results expressed as mean ± SD for lymph nodes with no PrPd (Negative,
n  = 8 [2 nodes × 2 sides – left and right – × 2 sheep]), or with low (Low,
n  = 8) or high (High + Clinical, n = 16) PrPd levels. (a) lymph nodes of the
head (medial retropharyngeal and submandibular) (b) lymph nodes of the
hind leg (inguinal and popliteal).
expression was in the low PrPd group (6.5 ± 0.9 vs. 5.7 ± 0.8
in the high PrPd group; P < 0.05). In contrast, no significant
differences in the labelling of this marker between sheep
groups were found for the lymph nodes draining the hind
legs.
No differences in the expression of CD79 were found in
any of the comparisons between sheep groups. However,
when the high PrPd group was re-divided into preclinical
and clinical cases, the latter showed significantly lower
number of CD79 positive cells in the head lymph nodes
than any of the other three groups (7.3 ± 0.5 vs. 8.4 ± 0.3,
8.3 ± 0.5 and 8.2 ± 0.7, for high PrPd, low PrPd and nega-
tive preclinical cases, respectively, with P values of <0.001,
<0.01 and <0.05, also respectively; Fig. 3). In the hind leg
lymph nodes, clinical cases also showed lower levels of
expression of this marker, although differences were not
statistically significant. Finally, in the lymph nodes of both
the head and hind legs PrPd negative sheep showed a sig-
nificantly lower (P < 0.05) number of CD21 positive cells
compared with the other two  groups, low PrPd and high
PrPd, which displayed similar levels of CD21+ cell immuno-
labelling (Table 3 and Fig. 3).
4. Discussion
4.1. General aspects of scrapie pathogenesis after
experimental subcutaneous injection
According to the results of our study, accumulation of
PrPd in the LRS after subcutaneous injection progresses
alongside the course of infection in a non-linear form as
it plateaus at around 500 dpi, well before onset of clini-
cal disease in most cases. In agreement with most studies
on the pathogenesis of sheep and goat scrapie, either by
natural or experimental routes, accumulation of PrPd in
the CNS appears to have a delayed onset in comparison
Fig. 3. Labelling of different immune cell markers in lymph nodes of the head (white bars) and hind legs (dashed bars) of sheep accumulating different
levels (negative, low and high) of PrPd in lymphoid tissues. Results expressed as mean values of cell counts for the different markers and standard deviations
(error  bars). Note that the group of “High” PrPd includes four sheep (two clinical and two preclinical), as explained in the text. Significant differences in
immune cell marker expression between sheep groups are indicated by different letters (for actual values refer to Table 3), so that values with different
letters are significantly different.
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Fig. 4. IHC of CNS and LRS samples from animals representative of different levels of PrPd immunolabelling and CD21+ and CD79+ positive cells. (A)–(D)
(sheep  devoid of PrPd immunolabelling), (E)–(H) (sheep with low magnitude of PrPd accumulation), (I)–(L) (sheep with high amounts of PrPd immunola-
belling) and (M)–(P) (sheep showing clinical signs of scrapie). PrPd labelling of obex (A, E, I and M)  and retropharyngeal lymph node (B, F, J and N) using
anti-PrPd antibody R145, showing the absence of labelling in scrapie negative sheep and a progressive number of labelled cells in sheep of the low, high
and  clinical groups. CD21 positive cells in retropharyngeal lymph nodes of sheep from the negative (C), low PrPd (G) high PrPd (K) and clinical (O) groups.
CD79 positive cells in the retropharyngeal LNs of sheep from the negative (D), low PrPd (H) high PrPd (L) and clinical (P) group. Original magnification 40×
with  the exception of A, E, I and M 100×.
with the LRS and seems to progress during the preclin-
ical and clinical phases, until clinical end point is reached
(Andreoletti et al., 2000; van Keulen et al., 2000; González
et al., 2010; Tabouret et al., 2010). At this point all affected
sheep show similar magnitudes of PrPd deposition in the
brain, although the rate or speed of accumulation appears
to differ from sheep to sheep; those differences cannot
always be explained by polymorphisms in the Prnp geno-
type of the recipient sheep but have been found to result
from an interaction between source and host genetic fac-
tors (González et al., 2012).
An early, consistent and high-level accumulation of PrPd
in the palatine tonsil and medial retropharyngeal LN has
been repeatedly documented in natural cases of scrapie in
sheep of different Prnp genotypes (Andreoletti et al., 2000;
González et al., 2006; Langeveld et al., 2006; Lacroux et al.,
2008) and goats (González et al., 2010) and also in experi-
mental sheep scrapie challenge by the oral route (Heggebo
et al., 2003; Ryder et al., 2009). This has been attributed by
some authors to an early contact of the infectious agent
with the lymphoid tissues associated with the gastroin-
testinal tract after ingestion (van Keulen et al., 2002; Ryder
et al., 2009), which would also explain the early and con-
sistent involvement of the Peyer’s patches observed in the
same studies. It is therefore surprising that the same two
lymphoid structures – medial retropharyngeal LN and pala-
tine tonsil – are those showing the highest magnitudes of
PrPd accumulation after subcutaneous scrapie challenge,
particularly at a preclinical stage of infection. One possible
explanation is that after early dissemination of the agent in
the bloodstream, it reaches the brain through the circum-
ventricular organs (Sisó et al., 2010a,b) and is re-circulated
in the interstitial and cerebrospinal fluid reaching the nasal
submucosa, or even the nasal cavity itself, through the crib-
riform plate (Weller et al., 2009). Scrapie agent in the nasal
submucosa could then enter afferent lymphatics that drain
to the medial retropharyngeal LN, while the agent in the
nasopharynx could accumulate in the pharyngeal tonsil
or pass to the oropharynx and then arrive in the palatine
tonsil; both these tonsils also drain towards the medial
retropharyngeal LN. This hypothesis could be sustained by
the early and consistent involvement of the circumventri-
cular organs in the preclinical sheep of this study, which
has been described in detail previously (Sisó et al., 2009).
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Also, the contribution of the haematogenous route in the
neuroinvasion after subcutaneous challenge is reinforced
by the absence of detectable PrPd in the ENS and cranial
mesenteric ganglion of approximately 50% of preclinical
scrapie cases, some of which were positive in the brain (see
Table 1).
4.2. Effect of codon 112 polymorphism on susceptibility
to and pathogenesis of scrapie
Previous publications have reported the influence of
the threonine amino acid at codon 112 of the PrP gene
on the susceptibility of ARQ/ARQ sheep to natural scrapie
(Ikeda et al., 1995), to sheep experimentally infected by
the oral route (Laegreid et al., 2008; González et al.,
2012) and to sheep orally and intracerebrally infected
with BSE (Saunders et al., 2009). This experiment sup-
ports those findings with respect to the subcutaneous
route of inoculation, both in terms of attack rates (incom-
plete in heterozygotes) and incubation period (markedly
protracted in the only heterozygote allowed to develop
clinical disease). In addition, our results suggest that a delay
in accumulation of PrPd occurs in MT  heterozygotes in
comparison to MM homozygotes at preclinical stages of
infection (478–529 dpi). Thus, two heterozygotes showed
little involvement of LRS tissues and just a trace of PrPd
or none at all in brain, and one showed widespread LRS
involvement but mild PrPd accumulation in the CNS. This
was in contrast with the findings in homozygotes which,
at comparable dpi, showed widespread PrPd accumulation
in LRS tissues and all were positive in the CNS. A possi-
ble explanation for this incomplete protective effect can
be extrapolated from studies in which VRQ/ARR infected
sheep were found to accumulate PrPSc of the VRQ – and
not of the ARR – polymorphism (Jacobs et al., 2011; Morel
et al., 2007). Similarly, “in vitro” studies have shown that the
M112T variant of PrPc does not easily convert to the PrPSc
isoform (Bossers et al., 2000) therefore it could be postu-
lated that in M112T heterozygotes the only PrPc that can
be converted to PrPd is the M112 one. This could explain
the close phenotypic similarity of PrPd accumulation in
homo- and heterozygotes and, because M112 PrPc is less
abundant in the latter, the delay of such accumulation
in M112T heterozygotes. Moreover, the M112T PrPc vari-
ant could actually interfere with M112 protein conversion
and accumulation; this phenomenon of allelic interference
has been observed in some murine scrapie models (Barron
et al., 2003) and in scrapie-ARR/ARQ heterozygotes (Caplazi
et al., 2004).
4.3. Effect of lymphadenectomy on the progression of
scrapie
Removal of the prefemoral LN, draining lymph from the
site of injection, either early or late after inoculation, did not
affect the magnitude nor the spread of PrPd accumulation in
the different tissues examined at comparable time points
after inoculation. This finding suggests that, after subcu-
taneous injection of scrapie, the infectious agent rapidly
disseminated through the body either because it: (i) gained
immediate access to the bloodstream through venous
capillaries in the subcutis, or (ii) drained to the regional LN
but, rather than being sequestered there, was re-circulated,
possibly through the lymph or directly into the blood. The
fact that the three sheep from which lymph was  collected
from the efferent lymphatics from the prefemoral nodes
before, during and after subcutaneous inoculation (Table 1)
became as efficiently infected (as judged by PrPd detection)
as those from which efferent lymph was not taken does
not disprove a re-circulation of the scrapie agent through
the efferent lymphatics as these were left in place until the
excision of the prefemoral LN several days later. The notion
of a low degree of primary infection of the regional lymph
node and an early recirculation and dissemination of the
scrapie agent is reinforced by the result that only one of
four ipsi-lateral nodes in the EL group and only two of four
in the LL group from M112M sheep showed PrPd accumula-
tion, and also by the bilateral PrPd accumulation in paired
lymphoid tissues during the preclinical stage of disease.
4.4. Scrapie-related changes in immune cell subsets
Finally, this study showed little change in the differ-
ent immune system cell subsets that can be attributed
to scrapie infection and/or PrPd accumulation in LNs. In
this respect, we have considered that the two  scrapie-
inoculated sheep which showed a complete absence of
detectable PrPd at post-mortem (J169 and J137 in Table 1)
are the negative controls, not only for lack of PrPd in the
LNs studied, but also for scrapie infection as such.
The lack of appreciable differences in CD3+, CD4+ and
CD8+ cells between LNs with and without PrPd could
be explained by the different distribution or lack of co-
localization of those cells (paracortex, with the exception
of some CD4+ve cells) and PrPd (follicles) within the nodes.
This explanation is consistent with the well documented
absence of PrPd in the thymus of scrapie infected sheep
(Andreoletti et al., 2000; Jeffrey et al., 2001), and suggests
little or no involvement of T cells in the pathogenesis of the
disease. The apparent increase of -positive T lympho-
cytes in PrPd positive lymph nodes is difficult to interpret
since such increase was  particularly noticeable in LNs with
low rather than high PrPd levels and was restricted to those
of the head but was  not observed in LNs of the hind leg.
However, the LNs of the head and particularly the medial
retropharyngeal LN, have been repeatedly shown to be the
earliest and most consistent lymph nodes to accumulate
PrPd in natural and experimental scrapie (van Keulen et al.,
1996; Andreoletti et al., 2000; Ryder et al., 2009; González
et al., 2010). Therefore, a scrapie-driven increase of  T
cell expression in such lymph nodes at early time points
(low PrPd levels) of infection cannot be ruled out.
Using flow cytometry, we  have previously reported
that subcutaneous injection of scrapie-brain homogenate
resulted in a reduction in the numbers of CD21+ cells in
the local LN within the first five hours after inoculation
(Eaton et al., 2009). However, this situation was reversed
with time, so that CD21+ cells were detected in increased
numbers in PrPd-positive lymph nodes at later stages of
preclinical infection when compared with PrPd-negative
lymph nodes of ARR/ARR sheep (Eaton et al., 2007). Using
IHC, the present study supports the results of the previous
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study (Eaton et al., 2007) by showing increased num-
bers of CD21+ cells early in the incubation period (low
PrPd levels) of scrapie. As lymph node FDCs are not rep-
resented in flow cytometry studies, they do not survive
the disaggregation process, the similarity of results of both
studies points towards mature B cells being those that are
actually increased during scrapie infection. This is in agree-
ment with electron microscopy studies on scrapie-infected
mouse spleens showing the phenomenon of “emperipole-
sis”, that is, the trapping of mature B cells by FDC processes
within the germinal centres of lymphoid follicles (Jeffrey
et al., 2000). However, the present study has not revealed
a quantitative correlation between the PrPd levels and B
cell increases, so that the latter would more appear to
be the result of infection itself rather than of the mag-
nitude of PrPd in the follicles. If the above hypothesis is
correct (increased numbers of CD21+ mature B cells), the
lower numbers of CD79+ cells in clinically affected sheep
would result from a decrease in immature B cells. Since
this change was unapparent in lymph nodes with high
PrPd levels from preclinical cases, it would be more likely
associated with other phenomena, either related to clinical
disease or to the more advanced age of the sheep. Ageing
has been shown to influence the pathogenesis of prion dis-
eases in the LRS of mice and to alter the microarchitecture
of the mantle zone (Mabbott, 2012), and the two clinically
affected sheep were approximately 10 month older than
the preclinical cases.
5. Conclusions
In conclusion, we have found that ARQ/ARQ sheep with
a threonine mutation at codon 112 are less susceptible
than methionine homozygotes to subcutaneous injection
of scrapie and that lymphadenectomy of the local draining
lymph node does not have any impact on the pathogenesis
of the infection. This suggests an early spread of the scrapie
agent throughout the body. Furthermore, clear changes in
immune cell population density attributable to scrapie are
restricted to increased numbers of CD21+ cells in lymph
nodes both close and far from the site of injection; such
increases appears to be related to the presence but not to
the level of PrPd in the affected nodes.
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